Efficacy Study of Radiotherapy Alone Versus CCRT With Temozolomide in Grade III Gliomas Without 1p/19q Codeletion

Inclusion criteria: * Newly diagnosed histologically proven supratentorial anaplastic gliomas.The histological diagnosis must be obtained from a neurosurgical resection or biopsy of a tumor including an open biopsy or stereotactic biopsy. * Absence of chromosome 1p/19q co-deletion * Age 18 years * Eastern Cooperative Oncology Group performance status of 0-1 * Stable or decreasing dose of steroids for 5 days prior to randomization * Meets 1 of the following RPA classifications:class III-V * Adequate hematologic, renal, and hepatic function * Written informed consent Exclusion criteria: * Prior chemotherapy within last 5 years * Prior radiotherapy of the head and neck area * Receiving concurrent investigational agents or has received an investigational agent within 30 days prior to randomization * Planned surgery for other diseases (e.g. dental extraction) * History of malignancy. Subjects with curatively treated cervical carcinoma in situ or basal cell carcinoma of the skin, or subjects who have been free of other malignancies for 5 years are eligible for this study * Pregnant or lactating women * Subject who disagree to follow acceptable methods of contraception * Concurrent illness including unstable heart disease despite appropriate treatment, history of myocardial infarction within 6 months, serious neurological or psychological disease, and uncontrolled infection * Subject unable to undergo Gd-MRI